Submission date
19/08/2002
Registration date
19/08/2002
Last edited
27/06/2012
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Retrospectively registered
? Protocol not yet added
? SAP not yet added
Results added
? Raw data not yet added
Study completed

Plain English Summary

Not provided at time of registration

Study website

Contact information

Type

Scientific

Contact name

Prof David Cunningham

ORCID ID

Contact details

Department of Medicine
Royal Marsden NHS Trust
Downs Road
Sutton
SM2 5PT
United Kingdom

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Protocol/serial number

RMH E/N 1169

Study information

Scientific title

Acronym

Study hypothesis

To compare the response rate and quality of life in patients having these regimens.

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type

Treatment

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Neuroendocrine tumours

Intervention

Two arms:
Regimen 1. Protracted venous infusion (PVI) 5FU 300 mg/m2/day over 24 weeks
Regimen 2. PVI 5FU 300 mg/m2/day over 24 weeks Mitomycin-C 7 mg/m2 (total dose must not exceed 56 mg) four courses over 24 weeks

Intervention type

Drug

Pharmaceutical study type(s)

Phase

Not Specified

Drug/device/biological/vaccine name(s)

5-Fluorouracil (5FU), mitomycin-C

Primary outcome measure

1. Response rate
2. Toxicity
3. Time to disease progression
4. Survival
5. Quality of life

Secondary outcome measures

No secondary outcome measures

Overall study start date

12/09/1995

Overall study end date

26/11/2003

Reason abandoned (if study stopped)

Eligibility

Participant inclusion criteria

1. Histological evidence of neuroendocrine tumours not amenable to surgery or radiotherapy
2. Patients evaluable for response must have bi-dimensionally measurable disease as assessed by chest X-ray or computed tomography (CT) scan
3. This disease must be outside previously irradiated areas

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

Not provided at time of registration

Participant exclusion criteria

Not provided at time of registration

Recruitment start date

12/09/1995

Recruitment end date

26/11/2003

Locations

Countries of recruitment

England, United Kingdom

Study participating centre

Department of Medicine
Sutton
SM2 5PT
United Kingdom

Sponsor information

Organisation

The Royal Marsden NHS Foundation Trust (UK)

Sponsor details

Downs Road
Sutton
SM2 5PT
England
United Kingdom

Sponsor type

Hospital/treatment centre

Website

ROR

https://ror.org/0008wzh48

Funders

Funder type

Hospital/treatment centre

Funder name

Royal Marsden Hospital (UK)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 15/07/2002 Yes No

Additional files

Editorial Notes